RxDoctor Payments Data

Olga Brusil, MD

Neurology · Glenview, ILNPI 1730275223

Payments from drug & device makers

$6,433in general payments, 2019–2025

Across 283 payments — averaging $22.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$802
  • Argenx US, Inc.$657
  • UCB, Inc.$474
  • AstraZeneca$453
  • Neurocrine Biosciences, Inc.$323
  • Biogen$299
  • plus $3K from 44 others

What the payments were for

  • Food & beverage$6,30598%
  • Education$1282%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,433 in reported general payments places this provider in the 70th percentile of 790 neurology providers in Illinois.

See all neurology providers in Illinois

Medicare billing

Part B allowed, 2024
$112,563
Medicare patients
193
Services billed
2,377

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Vyvgart HytruloEfgartigimod-Hyaluronidas-Qvfc22$506,953
PrivigenImmun Glob G(Igg)/Pro/Iga 0-5018$322,718
IngrezzaValbenazine Tosylate19$235,412
GammaplexImmun Glob G(Igg)/Gly/Iga 0-5015$190,519
Gabapentin300$11,358
RytaryCarbidopa/Levodopa20$6,874
Pregabalin122$4,323
Baclofen227$2,986
Diclofenac Sodium93$2,947
Levetiracetam44$1,849
Propranolol Hcl ErPropranolol Hcl23$1,492
Carbidopa-Levodopa ErCarbidopa/Levodopa42$1,301
Primidone23$1,239
Carbidopa-LevodopaCarbidopa/Levodopa36$1,146
Meloxicam259$1,087

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Argenx US, Inc.Vyvgart Hytrulo$657$506,95322 claims
CSL BehringPrivigen$62$322,71818 claims
Neurocrine Biosciences, Inc.Ingrezza$323$235,41219 claims
Amneal Pharmaceuticals LLCRytary$243$6,87420 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 790 neurology providers in Illinois.

Other neurology in Glenview

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →